Orion Pharma (DHA:ORIONPHARM) Cyclically Adjusted Revenue per Share: BDT47.10 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
72 GF Score
Price BDT30.10
GF Value BDT20.17
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Cyclically Adjusted Revenue per Share?

Orion Pharma DHA:ORIONPHARM -2.27% 72 Cyclically Adjusted Revenue per Share is BDT47.10 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.17 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Orion Pharma's adjusted revenue per share for the three months ended in Mar. 2026 was BDT6.354. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is BDT47.10 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Orion Pharma's average Cyclically Adjusted Revenue Growth Rate was -6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-14), Orion Pharma's current stock price is BDT30.10. Orion Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was BDT47.10. Orion Pharma's Cyclically Adjusted PS Ratio of today is 0.64.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Orion Pharma was 1.62. The lowest was 0.51. And the median was 0.73.


Orion Pharma  (DHA:ORIONPHARM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Orion Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=30.10/47.10
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Orion Pharma was 1.62. The lowest was 0.51. And the median was 0.73.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Orion Pharma Cyclically Adjusted Revenue per Share Related Terms


Orion Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Cyclically Adjusted Revenue per Share Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 52.55 52.63 49.19

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.15 49.19 48.60 47.28 47.10

DHA:ORIONPHARM vs CEG, VST, NRG: Cyclically Adjusted Revenue per Share Comparison

For the Utilities - Independent Power Producers subindustry, Orion Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Pharma Cyclically Adjusted PS Ratio vs Utilities - Independent Power Producers Industry

For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Orion Pharma's Cyclically Adjusted PS Ratio falls into.


DHA:ORIONPHARM
72GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orion Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.354/330.2130*330.2130
=6.354

Current CPI (Mar. 2026) = 330.2130.

Orion Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201509 11.812 237.945 16.392
201609 11.194 241.428 15.311
201612 8.255 241.432 11.291
201703 9.857 243.801 13.351
201706 11.438 244.955 15.419
201709 12.214 246.819 16.341
201712 9.589 246.524 12.844
201803 10.892 249.554 14.412
201806 11.843 251.989 15.519
201809 15.297 252.439 20.010
201812 8.127 251.233 10.682
201903 5.263 254.202 6.837
201906 8.510 256.143 10.971
201909 9.515 256.759 12.237
201912 6.568 256.974 8.440
202003 6.212 258.115 7.947
202006 10.387 257.797 13.305
202009 12.517 260.280 15.880
202012 10.234 260.474 12.974
202103 10.421 264.877 12.992
202106 13.121 271.696 15.947
202109 5.076 274.310 6.110
202112 3.224 278.802 3.819
202203 4.863 287.504 5.585
202206 28.127 296.311 31.345
202209 16.729 296.808 18.612
202212 17.088 296.797 19.012
202303 9.819 301.836 10.742
202306 15.879 305.109 17.186
202309 15.426 307.789 16.550
202312 9.126 306.746 9.824
202403 8.698 312.332 9.196
202406 12.138 314.175 12.758
202409 7.037 315.301 7.370
202412 3.677 315.605 3.847
202503 3.611 319.799 3.729
202506 3.119 322.561 3.193
202509 3.395 324.800 3.452
202512 3.197 324.054 3.258
202603 6.354 330.213 6.354

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of BDT47.10 mean?
Orion Pharma (DHA:ORIONPHARM) has a Cyclically Adjusted Revenue per Share of BDT47.10 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's Cyclically Adjusted Revenue per Share too high?
Orion Pharma's current Cyclically Adjusted Revenue per Share is BDT47.10. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Cyclically Adjusted Revenue per Share compare to CEG and VST?
Orion Pharma's Cyclically Adjusted Revenue per Share of BDT47.10 can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for an Utilities - Independent Power Producers company?
A good Cyclically Adjusted Revenue per Share depends on the Utilities - Independent Power Producers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orion Pharma and its competitors. Orion Pharma's current Cyclically Adjusted Revenue per Share is BDT47.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.17, compared to a current price of BDT30.10 — trading 49.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is BDT47.10. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Cyclically Adjusted Revenue per Share is BDT47.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT30.10 is trading 49.2% above its estimated GF Value™ of BDT20.17. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Cyclically Adjusted Revenue per Share: BDT47.10
  • GF Value™: BDT20.17 vs. price of BDT30.10 (49.2% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score

Get the complete analysis for DHA:ORIONPHARM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT30.10
Price
BDT20.17
GF Value